DLBS 2411

Drug Profile

DLBS 2411

Alternative Names: DLBS-2411

Latest Information Update: 25 Jun 2015

Price : $50

At a glance

  • Originator Dexa Medica
  • Class Antiulcers
  • Mechanism of Action Gene expression inhibitors; Proton translocating ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Peptic ulcer

Most Recent Events

  • 16 Dec 2015 Biomarkers information updated
  • 01 May 2015 Phase-III clinical trials in Peptic ulcer in Indonesia (PO) (NCT02262169)
  • 07 Oct 2014 Dexa Medica plans a phase III trial for Peptic ulcers in Indonesia (NCT02262169)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top